Rising Number of Smokers and Consumption of Alcohol Drive the Demand for Bronchiectasis Market

 

Smoking and consumption of alcohol has increased the risk of several kinds of lung diseases including bronchiectasis among others. This has been reported that every year in China, around 300 million people smoke more than 2,000,000 million cigarettes. It has been reported that many of the respiratory diseases are caused by the smoking and consumption of alcohol which directly impact to increase the demand of bronchiectasis diagnostic and treatment to treat the diseases, for this reason, the rising number of smokers and consumption of alcohol is acting as a driver for growing the demand of global bronchiectasis market.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-bronchiectasis-market

Data Bridge Market Research analyses that the bronchiectasis market is expected to grow at a CAGR of 6.0% in the forecast period of 2021 to 2028 and is expected to reach USD 894.52 million by 2028. For instance, As per the report of 2020, this has been indicated that in Italy, the prevalence and incidence rate of bronchiectasis increases with an increase in age and is the highest in the patient population of 75 years or over. Geriatric populations have weakened immune systems that, enhances the chances of getting disease affected. The increasing geriatric population demands the effective diagnostic and treatment approach, thus expected to boost up the bronchiectasis market growth.

Patient Population Suffering from Bronchiectasis is expected to drive the Market's Growth Rate

The prevalence of bronchiectasis is one of the leading causes of death and disabilities all over the world. It is estimated that worldwide, the cases of bronchiectasis are increasing with the highly reported cases across America, Australia, Europe, and New Zealand. This increasing patient population relies on an effective diagnostic and treatment approach to sustain a disease-free and healthy life, hence expected to provide the bronchiectasis market with lucrative growth. Increasing cases of chronic bronchiectasis have impacted the death rate, which ultimately raises the demand for an increased rate of bronchiectasis diagnostics and treatment for early detection of any symptoms related to the bronchiectasis. The bronchiectasis diagnostics and treatment help critical care patients provide healthy lives, allowing patients to save life. This is why the rising patient population suffers from bronchiectasis and is acting as the driver for bronchiectasis market growth.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020(Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral and Inhalation), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Abbott (U.S.), HERSILL (Spain), Home Oxygen Company (U.S.), Inogen, Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Medline Industries, Inc (U.S.), Ache Laboratories Farmaceuticos S.A. (Brazil), Horizon Therapeutics plc (Dublin), Janssen Pharmaceuticals, Inc. (Belgium), Trudell Medical International (Canada), GlaxoSmithKline plc (U.K.), AstraZeneca (U.S.), Pfizer Inc. (U.S.),  Merck & Co., Inc., (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bayer AG (Germany), Covis Pharma (Switzerland), Zydus Pharmaceuticals, Inc. (U.S.), Cipla Inc. (India) and  Electromed, Inc. (U.S.)

Data Points Covered in Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

Global bronchiectasis market is categorized into seven notable segments which are based on the disease type, severity, type, drugs type, route of administration, end user and distribution channel.

  • On the basis of disease type, the global bronchiectasis market is segmented into CF bronchiectasis and non-CF bronchiectasis. In 2021, non-CF bronchiectasis segment is expected to dominate the market with 60.73% market share and is expected to reach USD 552.44 million by 2028, growing with the highest CAGR of 6.3% in the forecast period of 2021 to 2028 because non‐cystic fibrosis bronchiectasis often co-exists with other respiratory conditions such as chronic obstructive pulmonary disease (COPD). The prevalence of NCFB is increasing, particularly in women and older individuals.
  • On the basis of severity, the global bronchiectasis market is segmented into mild to moderate and moderate-to-severe. In 2021, mild to moderate segment is expected to dominate the market, growing with the highest CAGR of 6.1%

In 2021, mild to moderate segment is expected to dominate the market

In 2021, mild to moderate segment is expected to dominate the market, growing with the highest CAGR of 6.1% in the forecast period of 2021 to 2028 as bronchiectasis is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections, these symptoms causes life saver issues in patient’s day-to-day life. So, these symptoms are seen in the bronchiectasis's initial stage, and treatment can be done on the initial stage.

  • On the basis of type, the global bronchiectasis market is segmented into diagnosis and treatment. In 2021, treatment segment is expected to dominate the market, growing with the highest CAGR of 6.2% in the forecast period of 2021 to 2028 because bronchiectasis is the life-long disease and required continuous treatment. The overall treatment cost for the bronchiectasis is quite high and now consider in some reimbursement policies. Moreover, technological advancement also plays an important role in the treatment of bronchiectasis.
  • On the basis of drug type, the global bronchiectasis market is segmented into branded and generics. In 2021, branded segment is expected to dominate the market growing with the CAGR of 6.0% in the forecast period of 2021 to 2028. However, generics segment is growing with the highest CAGR of 6.6% in the forecast period of 2021 to 2028 because products offered by many companies are the patent formulation with high cost and consumption rate.
  • On the basis of route of administration, the global bronchiectasis market is segmented into oral, parenteral and inhalation. In 2021, inhalation segment is expected to dominate the market, growing with the highest CAGR of 6.5% in the forecast period of 2021 to 2028 because inhalation route of administration provide direct delivery of medication to the lungs by avoiding first pass metabolism.
  • On the basis of end user, the global bronchiectasis market is segmented into hospitals, clinics, home healthcare and others. In 2021, hospitals segment is expected to dominate the market, growing at the highest CAGR of 6.5% in the forecast period of 2021 to 2028 because hospital is the first place for the diagnosis of serious respiratory diseases. Moreover, hospitals are well equipped with advanced instruments
  • On the basis of distribution channel, the global bronchiectasis market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is expected to dominate the market growing with the highest CAGR of 6.2% in the forecast period of 2021 to 2028 as hospital pharmacy has wide range of products according to the patients need and demand. Moreover, hospital pharmacy has skilled professionals so that they can guide the patients about the medication usage.

Major Players

Data Bridge Market Research recognizes the following companies as the major bronchiectasis market players in bronchiectasis market are Abbott (U.S.), HERSILL (Spain), Home Oxygen Company (U.S.), Inogen, Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Medline Industries, Inc (U.S.), Ache Laboratories Farmaceuticos S.A. (Brazil), Horizon Therapeutics plc (Dublin), Janssen Pharmaceuticals, Inc. (Belgium), Trudell Medical International (Canada), GlaxoSmithKline plc (U.K.), AstraZeneca (U.S.), Pfizer Inc. (U.S.),  Merck & Co., Inc., (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bayer AG (Germany), Covis Pharma (Switzerland), Zydus Pharmaceuticals, Inc. (U.S.), Cipla Inc. (India) and  Electromed, Inc. (U.S.)

Market Development

  • In October 2020, Electromed, Inc. launched SmartVest Connect App compatible with iOS and android. The product launched is one of the personalized high frequency chest wall oscillation therapy management which has enhanced the treatment plans in patients suffering from bronchiectasis among other lung disease. This new product has allowed the healthcare teams and patients to tack therapy on time and improve therapy adherence and patient outcomes.
  • In September 2020, Teva Pharmaceutical USA Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) launched two digital inhalers that are AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir Digihaler (fluticasone propionate) Inhalation Powder in the United States. These two products have been indicated to provide with the sudden relief from respiratory problems. These two products launch helped the company earn lucrative growth by enhancing product sales.
  • In July 2019, Pfizer Inc. completed the acquisition of Array BioPharma Inc., a company focused on the discovery, development and commercialization of a variety of medicines indicated for treatment of several kinds of diseases. This acquisition boosted its research and development activities and advanced its product portfolio.

Regional Analysis

Geographically, the countries covered in the bronchiectasis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in bronchiectasis market during the forecast period

North America dominated the bronchiectasis market owing to the increasing clinical trials and research development for prevention of serious respiratory diseases among the adults. North America will continue to dominate the bronchiectasis market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and launch of new products in this region.

Asia-Pacific is estimated to be the fastest growing region in bronchiectasis market

Asia-Pacific is expected to grow during the forecast period due to the increasing demand of effective treatment in this region. In addition to this, rise in prevalence of respiratory diseases such as asthma, COPD, tuberculosis and rising geriatric population in this region.

COVID-19 Impact Analysis

COVID-19 has a positive impact over the bronchiectasis market.  According to the study, the rate of COVID-19 was higher in patients with bronchiectasis than in those without. Another study concluded that COVID-19 patients with bronchiectasis had a more severe infection than those without. COVID-19 patients with bronchiectasis had a much higher rate of supplemental oxygen, ECMO, and mortality in this study than those without bronchiectasis. Despite having similar ICU admission rates, COVID-19 patients with bronchiectasis had a worse clinical course than those without bronchiectasis, despite having similar severity when initially admitted to the ICU. Bronchiectasis patients' susceptibility to and severity of COVID-19 is likely to be increased by impaired mucociliary clearance and chronic inflammation in the airway. Furthermore, COVID-19 may aggravate bronchiectasis. COVID-19 patients with bronchiectasis had a significantly higher prevalence of COPD (57.6 percent versus 19.3 percent) and asthma (62.1 percent versus 17.2 percent) than the overall bronchiectasis population in South Korea.

In conclusion, these studies suggest provides evidence that patients with bronchiectasis may be more susceptible to COVID-19. Furthermore, COVID-19 patients with bronchiectasis had more severe clinical manifestations and poorer outcomes than those without. Therefore, the bronchiectasis market was moderately affected by the pandemic as the patient pool for both diseases was similar.

Frequently Asked Questions (FAQs)

For more detailed information about the bronchiectasis market report, click here – https://www.databridgemarketresearch.com/reports/global-bronchiectasis-market